Chronic periadolescent leuprolide exposure affects the development of reproductive physiology and behavior of female and male rats differently, but both mature after treatment termination

• Published in: Biology of sex differences Vol. 14; no. 1; pp. 1 - 14
• Main Authors: Guarraci, Fay A, Avendano, Layla, Kelly, Megan, Estoesta, Cleriza, Sencherey, Bernard, Valdivia, Hannah S, Gale, Amanda, Yepez, Lily, Belfield, Jasmine B, Carter, Kristen M, Williams, Natalie, Gore, Andrea C
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2023; BioMed Central; BMC
• Subjects: Acetates; Adolescent; Animals; Child; Estrous cycle; Estrus; Female; Gender Identity; GnRH agonist; Humans; Leuprolide; Leuprolide - pharmacology; Leuprolide - therapeutic use; Male; Partner preference; Physiological aspects; Preputial separation; Puberty, Precocious - drug therapy; Rats; Rats, Long-Evans; Sexual motivation; Vaginal opening; Puberty; Vaginal opening; Partner preference; Copulatory behavior; GnRH agonist; Sexual behavior; Sexual motivation; Estrous cycle; Paced mating; Preputial separation
• ISSN: 2042-6410; 2042-6410
• DOI: 10.1186/s13293-022-00485-5

GnRH agonists have been used to halt the development of puberty in children with precocious puberty since the 1980s. Recently, drugs like Lupron Depot (leuprolide acetate), have been used to suppress pubertal progression in adolescents who are questioning their gender identity. However, few preclinical studies have been conducted to investigate potential effects of using GnRH agonists in this context. The present study tested the effects of daily leuprolide treatment (50 µg/kg, postnatal day (PD) 25-50) on pubertal onset in female (i.e., vaginal opening) and male (i.e., preputial separation) Long-Evans rats. The first estrous cycle immediately after vaginal opening was also measured. Sexual behavior and sexual motivation were tested using the partner-preference paradigm. Female rats were tested during the first behavioral estrus after treatment ended (between PD 51-64). Male rats were tested weekly for four consecutive weeks starting three days after treatment ended (PD 53). Consistent with previous findings, leuprolide significantly delayed pubertal onset in both female and male rats. In addition, the first estrous cycle during the treatment period was disrupted by leuprolide, as indicated by a failure to cycle into estrus after vaginal opening until treatment ended. However, leuprolide affected neither sexual motivation nor fertility when female rats were tested within 14 days of leuprolide treatment ending. In contrast, the development of copulatory behavior and sexual motivation was significantly delayed by leuprolide in male rats; however, mature reproductive behavior was observed by the fourth week post-treatment. Taken together with previous findings, the present results indicate that male rats may be more sensitive to periadolescent leuprolide administration, taking longer to overcome the effects of leuprolide than female rats. Nevertheless, not long after leuprolide treatment is discontinued, sex-typical reproductive physiology and behavior emerge fully in female and male rats, indicating that the drug's effects are not permanent. If translatable to humans, leuprolide may be a reversible option to give adolescents more time to consider their gender identity with minimal long-term effects on sexual development.